Long-Term NMDAR Antagonism Correlates Weight Loss With Less Eating
| Autor: | Hui-Ran Fan, Yu-Hua Yan, Tai-Lin Zhu, Fei Li, Shining Deng, Yan-Mei Liu, Wei-Guang Li, Bing-Ke Ma |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Drug
obesity medicine.medical_specialty lcsh:RC435-571 media_common.quotation_subject high fat food 03 medical and health sciences 0302 clinical medicine Weight loss lcsh:Psychiatry Internal medicine medicine Overeating NMDA (N-methy-D-aspartate receptor) Original Research media_common Psychiatry business.industry Memantine Antagonist medicine.disease Obesity 030227 psychiatry Psychiatry and Mental health Endocrinology NMDA receptor Anxiety memantine weight loss medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Frontiers in Psychiatry, Vol 10 (2019) Frontiers in Psychiatry |
| ISSN: | 1664-0640 |
| DOI: | 10.3389/fpsyt.2019.00015 |
| Popis: | Memantine hydrochloride is an uncompetitive N-methyl-D-aspartate (NMDA) antagonist for treatment of moderate-to-severe Alzheimer's disease. Several studies have shown that memantine can significantly correct the binge-like eating behavior in human and animal models. People with overeating behavior are more likely to be obese. Therefore, we suppose that memantine would be a good candidate for the treatment of obesity. In this study, memantine was shown to increase weight loss in obese mice induced by high fat diet. Memantine was shown to decrease food intake without inducing abdominal discomfort and anxiety, suggesting that this compound would be a good candidate drug for obesity control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|